Amryt Pharma has today announced record quarterly revenues as it reaffirmed its full year revenue guidance for 2022.
The company, which focuses on the development and commercialisation of treatments for orphan and rare diseases patients, said its first quarter revenues rose by 22.1% to $59.1m from the same time last year.
The company also marked its ninth consecutive quarter of positive EBITDA generation.
Last month, a European Medicines Agency (EMA) committee recommended the approval of the use of Amryt's Filsuvez product in the EU for the treatment of partial thickness wounds associated with Epidermolysis Bullosa (EB) in patients aged over six months.
"This recommendation for the approval of Filsuvez in Europe is the most significant milestone in Amryt's history and represents a major positive development for European patients that suffer from this debilitating condition and is the culmination of years of hard work from all the Amryt team," the company's chief executive Joe Wiley said.
"If approved, Filsuvez would be our fourth commercial product and we already have in place the team, financial flexibility, systems and global infrastructure to bring it to market and to execute our significant growth plan," Joe Wiley said.
"We are very excited by the potential to deliver Filsuvez to European patients in need as soon as possible," he added.
"Given the strong performance of our business year to date, we are today reaffirming our full year 2022 revenue guidance of $260-$270m which represents growth of 17%-21% over 2021," the CEO said.
Today's results also show that the company's Metreleptin drug continues to grow strongly and delivered 25.7% annual growth in the first quarter, while the relaunch of its Mycapssa drug is progressing well.
